ClinicalTrials.gg

Program

futibatinib

Also written as “Futibatinib”, “TAS-120” and “futibatinib, fulvestrant”.

Its studies are mostly in Cholangiocarcinoma · Neoplasm Metastasis · Adenocarcinoma Of Esophagus · Biliary Tract Neoplasms · Breast Neoplasms, led by Otsuka.

Furthest: phase 3, since Sep 16, 201910 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka104 open or runningphase 3since Sep 16, 2019Jan 23, 2014Dec 2026phase 2 · NCT05727176

Also a collaborator on its studies: Merck.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 23, 2014First study: phase 2 study in CholangiocarcinomaFirst studyNCT02052778 · 407 enrolled · United States, Australia, Canada and more
  2. Jun 24, 2019Phase 2 study in Breast NeoplasmsNCT04024436 · 64 enrolled · United States, Canada, France and more
  3. Sep 16, 2019Phase 3 study in Advanced CholangiocarcinomaNCT04093362 · 10 enrolled · United States, Argentina, Australia and more
  4. Dec 3, 2019Phase 2 study in Neoplasm MetastasisNCT04189445 · 115 enrolled · United States, Belgium, France and more
  5. Oct 15, 2020Phase 2 study in Advanced and Metastatic Urothelial CancerNCT04601857 · 43 enrolled · United States, France, Spain
  6. Jul 6, 2021Phase 1 study in Carcinoma, Non-Small-Cell LungNCT04965818 · 38 enrolled · United States
  7. Jan 23, 2023Phase 2 study in CholangiocarcinomaNCT05727176 · 120 planned · United States, Argentina, Australia and more
  8. Jul 6, 2023Phase 2 study in Adenocarcinoma Of EsophagusNCT05945823 · 53 enrolled · United States, France, Germany and more
  9. Jun 28, 2024Phase 3 study in Neoplasm MetastasisNCT06506955 · 15 enrolled · United States, France, South Korea and more
  10. Jul 3, 2026Phase 3 study in Biliary Tract NeoplasmsNCT07710885 · 784 planned · Australia, Japan, South Korea and more

Ahead

  1. Dec 2026Primary completion: phase 2 study in CholangiocarcinomaNCT05727176
  2. Apr 2027Primary completion: phase 3 study in Neoplasm MetastasisNCT06506955
  3. Apr 30, 2030Primary completion: phase 3 study in Biliary Tract NeoplasmsNCT07710885

TargetBeta

“Fibroblast growth factor receptor inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
nintedanibruleBoehringer Ingelheimphase 476
infigratinibruleBridgeBiophase 317

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07710885Biliary Tract Neoplasms · Australia, Japan, South Korea and more3RecruitingApr 30, 2030784
NCT06506955Neoplasm Metastasis · United States, France, South Korea and more3Active, not recruitingApr 202715
NCT05945823Adenocarcinoma Of Esophagus · United States, France, Germany and more2Active, not recruitingOct 1, 202653
NCT05727176Cholangiocarcinoma · United States, Argentina, Australia and more2RecruitingDec 2026120
NCT04965818Carcinoma, Non-Small-Cell Lung · United States1TerminatedJun 11, 202338
NCT04601857Advanced and Metastatic Urothelial Cancer · United States, France, Spain2TerminatedMar 8, 202443
NCT04189445Neoplasm Metastasis · United States, Belgium, France and more2TerminatedNov 11, 2024115
NCT04093362Advanced Cholangiocarcinoma · United States, Argentina, Australia and more3TerminatedApr 22, 202410
NCT04024436Breast Neoplasms · United States, Canada, France and more2TerminatedMay 31, 202364
NCT02052778Cholangiocarcinoma · United States, Australia, Canada and more2CompletedOct 1, 2020407

How it is read

Names in the registry

  • “Futibatinib”, 7 entries
  • “TAS-120”, 1 entry
  • “futibatinib”, 1 entry
  • “futibatinib, fulvestrant”, 1 entry
  • “Futibatinib plus Fulvestrant”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.